MGNX

MacroGenics, Inc.

15.43 USD
-0.18 (-1.15%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MacroGenics, Inc. stock is up 6.56% since 30 days ago. The next earnings date is May 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 April’s closed higher than March. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Mar 19:33 21 Jun, 2024 20.00 CALL 87 1820
13 Mar 19:33 21 Jun, 2024 20.00 CALL 85 1820
20 Mar 16:05 17 May, 2024 15.00 CALL 150 12
22 Mar 17:34 17 May, 2024 15.00 CALL 149 156
01 Apr 18:18 21 Jun, 2024 10.00 PUT 500 153
05 Apr 16:18 17 May, 2024 20.00 CALL 199 21
10 Apr 16:30 21 Jun, 2024 20.00 CALL 557 2518
12 Apr 19:23 21 Jun, 2024 20.00 CALL 105 3123
15 Apr 13:48 19 Jul, 2024 20.00 CALL 62 86
22 Apr 16:00 21 Jun, 2024 15.00 CALL 100 1075

About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer. The company also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4.

  • TD Cowen
    Tue Apr 9, 06:36
    buy
    upgrade
  • JP Morgan
    Thu Apr 4, 08:54
    buy
    confirm